Clinical Trials Browser

Breast Neoplasms

Carcinoma, Adenoid Cystic

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

Lymphoma, B-Cell, Marginal Zone

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Inflammatory Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

HR+/HER2- Breast Cancer

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Breast Neoplasms

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Urinary Bladder Neoplasms

Breast Neoplasms

Breast Neoplasms

HR-positive,HER2-negative Breast Cancer

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Breast Neoplasms

Adenocarcinoma of the Esophagogastric Junction

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Clinical Trials

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

EIC-SNACC

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

TARMAC

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

NeoSACT

MK-5890-003

TARMAC

neoMono

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

PELICAN

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

ARIADNE

FASCINATE-N

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

FAST

NeoHunter

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

GAIN INST

SAFIR02_Breast

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

SPRING

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

NeoTENNIS

QUEEN-Neo

TP-II

KEYPARTNER

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

GAMEC-II

POLO

SMA-BC-002

MEMORI

ANZAC

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer